Report on patients' access to cancer drugs 'uses flawed methods to reached flawed conclusions'
A leading epidemiologist has attacked Swedish research that looked at inequalities in patients' access to cancer drugs across Europe and the world. In a commentary published in the September issue of the cancer journal, Annals of Oncology, Professor Michel Coleman says the Karolinska report is so badly flawed that no safe conclusions can be drawn from it about cancer survival, and he highlights the role played by a major drug company in funding the research.
[ Ga naar het volledige artikel toe ]
Categorie: farma - kanker
[Reinig uw lichaam met de Chlorella alg -
100% plantaardig ]